Riociguat (Adempas®)

Assessment Status Rapid Review Complete
Drug Riociguat
Brand Adempas®
Indication For the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).
Assessment Process
Rapid review commissioned 11/04/2014
Rapid review completed 16/05/2014
Rapid review outcome Full HTA recommended at the current price.

The HSE has approved reimbursement following confidential price negotiations.